Innate lymphoid cells prevent graft-versus-host disease via IL-9-driven T-cell senescence

Area of Science:

• Immunology
• Cell Biology
• Hematology

Background:

• Innate lymphoid cells (ILCs) are crucial for tissue homeostasis and immune regulation.
• The precise mechanisms by which ILCs interact with and modulate T cells are not fully elucidated.
• Understanding ILC-T cell crosstalk is vital for advancing immune-based therapies.

Purpose of the Study:

• To investigate the immunomodulatory effects of ILCs on T cells.
• To determine the role of IL-9 in ILC-mediated T cell responses.
• To assess the therapeutic potential of ILCs in mitigating graft-versus-host disease (GVHD).

Main Methods:

• Differentiation of ILC2s and ILC3s from hematopoietic stem cells (HSCs).
• Co-culture experiments with ILCs and T cells to assess proliferation, cytokine production, and surface receptor expression.
• Analysis of senescence-related protein expression in T cells.
• IL-9 blockade and exogenous IL-9 addition experiments.
• In vivo studies using human xenogeneic and murine allogeneic hematopoietic cell transplantation (HCT) models.

Main Results:

• ILCs suppressed T cell proliferation and enhanced cytokine production.
• ILCs upregulated T cell senescence markers (CD57, KLRG1, TIGIT, TIM3) and senescence-related proteins (p16, p21, p53, GATA4, NF-κB).
• IL-9 was identified as the key mediator of ILC-driven T cell senescence, with blockade preventing and exogenous IL-9 inducing senescence.
• In vivo, ILCs demonstrated T cell modulation and induced senescence in both human and murine transplantation models.

Conclusions:

• HSC-derived ILCs, through IL-9 production, induce T cell senescence.
• ILC-mediated T cell senescence is a mechanism to mitigate GVHD in HCT.
• These findings highlight the therapeutic potential of ILCs in managing immune-related complications post-transplantation.